FUTURE PERSPECTIVES OF PHARMACOGENOMICS IN PERSONALIZED MEDICINE
Abstract
By making patient-specific medication therapy possible, developments in pharmacogenomics and artificial intelligence (AI) are revolutionising personalised medicine. Pharmacogenomics addresses interindividual variability in treatment outcomes by examining the ways in which genetic variants impact medication metabolism, effectiveness, and safety. Genetic variations in drug-metabolizing enzymes, transporters, and targets are important factors that influence both therapeutic response and adverse drug reactions, according to recent studies. However, conventional analytical methods face considerable difficulties due to the size and complexity of genetic and clinical data. AI has become a potent tool for analysing high-dimensional pharmacogenomic datasets, identifying gene–drug interactions, and more accurately predicting medication responses. This is especially true of machine learning and deep learning techniques.
Keywords:
Pharmacogenomics, Precision, Drug Response Prediction, Variability, Genetic Variability, Healthcare
Downloads
Download data is not yet available.
References
1. Rao C. Evaluation of antiulcer activity of Picrasma quassioides Bennett aqueous extract in rodents. Vedic Res Int Phytomed. 2013.
2. Gindi S, Mehta T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro antioxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013;2:636-649.
3. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):485-490.
4. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Adv Clin Med.
5. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025;20-.
6. Dara SR. An overview of the use of natural indicators in acid-base titrations. UPI J Pharm Med Health Sci. 2024;4(2):29-35. doi:10.37022/jpmhs.v4i2.103.
7. Adiki SK, Lahari K, Dey B, Khalf AM, Al-Sharif SM, Diaf SR, et al. Validated UV method development for the simultaneous estimation of rabeprazole sodium and cinitapride in tablets.
8. Rani CHU, Sumalatha G, Rao CB, Varalakshmi TN. Alzheimer’s disease: pharmacotherapeutic interventions. Int J Pharm Chem Sci. 2013;2(2).
9. Sarvani V, Elisha RP, Nama S, Pola LM, Rao CB. Process validation: an essential process in pharmaceutical industry. Int J Med Chem Anal. 2013;3(2):49-52.
10. Dey B, Katakam P, Mitra A, Chandu BR. Comparative evaluation of hypoglycemic potentials of Eucalyptus spp. leaf extracts and their encapsulations for controlled delivery. J Pharm Drug Deliv Res. 2014;3(2).
11. Schilsky RL. Implementing personalized cancer care. Am Soc Clin Oncol Educ Book. 2023;43:e3-e10.
12. Gupta PD. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift. Indian J Pharm Sci. 2015;77(2):135-141.
13. Budd WT, Meyers G, Dilts JR, O'Hanlon K, Woody JR, Bostwick DG, et al. Next generation sequencing reveals disparate population frequencies among cytochrome P450 genes: clinical pharmacogenomics of the CYP2 family. Int J Comput Biol Drug Des. 2016;9(1-2):54-86. doi:10.1504/IJCBDD.2016.074984.
14. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111(1):16-24. doi:10.1182/blood-2007-04-077412.
15. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
16. Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK. Pharmacogenomics: an evolving clinical tool for precision medicine. Cleve Clin J Med. 2020;87(2):91-99.
17. Leil TA, Kasichayanula S, Boulton DW, LaCreta F. Evaluation of 4β-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e120.
18. Schultze-Mosgau MH, Lasseter KC, Marbury T, Loewen S, Riecke K. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020;60(8):1030-1038. doi:10.1002/jcph.1608.
19. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293. doi:10.1056/NEJMoa044503.
20. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438-445. doi:10.1016/j.jmoldx.2016.01.003.
2. Gindi S, Mehta T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro antioxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013;2:636-649.
3. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):485-490.
4. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Adv Clin Med.
5. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025;20-.
6. Dara SR. An overview of the use of natural indicators in acid-base titrations. UPI J Pharm Med Health Sci. 2024;4(2):29-35. doi:10.37022/jpmhs.v4i2.103.
7. Adiki SK, Lahari K, Dey B, Khalf AM, Al-Sharif SM, Diaf SR, et al. Validated UV method development for the simultaneous estimation of rabeprazole sodium and cinitapride in tablets.
8. Rani CHU, Sumalatha G, Rao CB, Varalakshmi TN. Alzheimer’s disease: pharmacotherapeutic interventions. Int J Pharm Chem Sci. 2013;2(2).
9. Sarvani V, Elisha RP, Nama S, Pola LM, Rao CB. Process validation: an essential process in pharmaceutical industry. Int J Med Chem Anal. 2013;3(2):49-52.
10. Dey B, Katakam P, Mitra A, Chandu BR. Comparative evaluation of hypoglycemic potentials of Eucalyptus spp. leaf extracts and their encapsulations for controlled delivery. J Pharm Drug Deliv Res. 2014;3(2).
11. Schilsky RL. Implementing personalized cancer care. Am Soc Clin Oncol Educ Book. 2023;43:e3-e10.
12. Gupta PD. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift. Indian J Pharm Sci. 2015;77(2):135-141.
13. Budd WT, Meyers G, Dilts JR, O'Hanlon K, Woody JR, Bostwick DG, et al. Next generation sequencing reveals disparate population frequencies among cytochrome P450 genes: clinical pharmacogenomics of the CYP2 family. Int J Comput Biol Drug Des. 2016;9(1-2):54-86. doi:10.1504/IJCBDD.2016.074984.
14. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111(1):16-24. doi:10.1182/blood-2007-04-077412.
15. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
16. Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK. Pharmacogenomics: an evolving clinical tool for precision medicine. Cleve Clin J Med. 2020;87(2):91-99.
17. Leil TA, Kasichayanula S, Boulton DW, LaCreta F. Evaluation of 4β-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e120.
18. Schultze-Mosgau MH, Lasseter KC, Marbury T, Loewen S, Riecke K. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020;60(8):1030-1038. doi:10.1002/jcph.1608.
19. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293. doi:10.1056/NEJMoa044503.
20. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438-445. doi:10.1016/j.jmoldx.2016.01.003.
Published
02/06/2026
Statistics
2 Views | 0 Downloads
Citatons
How to Cite
[1]
S. Rudra, “FUTURE PERSPECTIVES OF PHARMACOGENOMICS IN PERSONALIZED MEDICINE”, Int J Indig Herb Drug, vol. 11, no. 2, pp. 9-13, Jun. 2026.
Issue
Section
Review Articles
Copyright © Author(s) retain the copyright of this article.
.